Pediatric Allergy and Immunology, Год журнала: 2025, Номер 36(4)
Опубликована: Апрель 1, 2025
Abstract Epcutaneous immunotherapy (EPIT) is a novel, non‐oral route of allergen immunotherapy, utilizing the skin and its robust density epidermal Langerhans cells (LC) for antigen presentation. This space non‐vascularized impermeable, which limits exposure into bloodstream but preserves presentation to regional lymph nodes generate gut‐homing regulatory T cells. The EPIT patch utilizes natural water loss from absorb electrosprayed through condensation. represents an alternative, food allergy, with good efficacy strong safety profiles across multiple phase 2 3 studies milk peanut. Efficacy appears best in very young children (1–3 years old), has been shown continue enhance extended treatment duration up 36 months. slightly older ages 4–11 age less clear, be better 4–7 age. In clinical trials peanut EPIT, most subjects experienced adverse effects, mainly mild‐to‐moderate reactions localized around placement site, improve continued wear. Rates treatment‐related anaphylaxis have low all ages, ranging 1.6% 4%, were lowest infant toddler population. While further (1‐ 3‐year‐olds) (4‐ 7‐year‐olds) are ongoing, potentially valuable addition current landscape allergy therapies, particular infants toddlers where families may seeking treatment. image
Язык: Английский